ARTICLE | Company News
SignalGene other research news
October 8, 2001 7:00 AM UTC
SGI published in Endocrinology evidence that 4-hydroxytamoxifen (OHT), the active metabolite of the breast cancer drug Tamoxifen, selectively blocks ERR-beta and ERR-gamma activity in tissue culture. ...